Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00024180 · ClinicalTrials.gov registry record · Phase 1
FR901228 in Treating Patients With Hematologic Cancer
A Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00024180 is a Phase 1 study that has completed, run by Ohio State University Comprehensive Cancer Center.
The verdict
NCT00024180, a Phase 1 study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of FR901228 in treating patients who have hematologic cancer.
Interventions
- DRUG romidepsin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-01 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00024180
The ClinicalTrials.gov registry entry for NCT00024180 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which romidepsin is the first listed.
NCT00024180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00024180 about?
NCT00024180 is a clinical study titled "FR901228 in Treating Patients With Hematologic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of FR901228 in treating patients who have hematologic cancer.
What is the current status of trial NCT00024180?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-01. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00024180?
The interventions under investigation include: romidepsin (DRUG).
Who is sponsoring clinical trial NCT00024180?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.